MEDICINOVA, INC. (MNOV) Operating Margin
- Operating margin · 12 months: Value -1287.41%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1287.41% | Operating income / revenue. Period ending 2026-06-30. $-11.85M ÷ $920.48K × 100 ≈ -1287.41% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -11.85M USD | Operating Income (Loss) |
| Revenue | 920.48K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 5.10M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-11.85M | $920.48K | (m) | $5.10M | (m) | -1287.41% |
| 2026-03-31 | $-12.92M | $596.64K | (m) | $6.20M | (m) | -2164.84% |
| 2025-12-31 | $-13.28M | $409.66K | (m) | $6.70M | (m) | -3242.47% |
| 2025-09-30 | $-13.37M | (m) | (m) | $7.10M | (m) | (m) |
| 2025-06-30 | $-13.30M | (m) | (m) | $7.30M | (m) | (m) |
| 2025-03-31 | $-12.74M | (m) | (m) | $6.80M | (m) | (m) |
| 2024-12-31 | $-12.68M | (m) | (m) | $6.80M | (m) | (m) |
| 2024-09-30 | $-11.98M | (m) | (m) | $6.60M | (m) | (m) |
| 2024-06-30 | $-9.82M | (m) | (m) | $5.50M | (m) | (m) |
| 2024-03-31 | $-10.07M | (m) | (m) | $5.60M | (m) | (m) |
| 2023-12-31 | $-9.90M | $1.00M | (m) | $5.30M | (m) | -990.03% |
| 2023-09-30 | $-10.64M | (m) | (m) | $5.60M | (m) | (m) |
| 2023-06-30 | $-13.39M | (m) | (m) | $7.20M | (m) | (m) |
| 2023-03-31 | $-14.18M | (m) | (m) | $8.10M | (m) | (m) |
| 2022-12-31 | $-14.63M | (m) | (m) | $8.70M | (m) | (m) |
| 2022-09-30 | $-13.50M | (m) | (m) | $8.50M | (m) | (m) |
| 2022-06-30 | $-13.20M | (m) | (m) | $8.20M | (m) | (m) |
| 2022-03-31 | $-13.42M | (m) | (m) | $8.10M | (m) | (m) |
| 2021-12-31 | $-10.22M | $4.04M | (m) | $8.10M | (m) | -253.02% |
| 2021-09-30 | $-11.13M | (m) | (m) | $8.10M | (m) | (m) |
| 2021-06-30 | $-11.25M | (m) | (m) | $8.20M | (m) | (m) |
| 2021-03-31 | $-11.46M | (m) | (m) | $7.90M | (m) | (m) |
| 2020-12-31 | $-14.18M | (m) | (m) | $7.10M | (m) | (m) |
| 2020-09-30 | $-13.39M | (m) | (m) | $7.10M | (m) | (m) |
| 2020-06-30 | $-12.30M | (m) | (m) | $6.10M | (m) | (m) |
| 2020-03-31 | $-11.98M | (m) | (m) | $5.40M | (m) | (m) |
| 2019-12-31 | $-14.03M | (m) | (m) | $5.70M | (m) | (m) |
| 2019-09-30 | $-12.30M | (m) | (m) | $4.10M | (m) | (m) |
| 2019-06-30 | $-16.68M | (m) | (m) | $5.30M | (m) | (m) |
| 2019-03-31 | $-15.90M | (m) | (m) | $5.20M | (m) | (m) |
| 2018-12-31 | $-15.59M | (m) | (m) | $5.30M | (m) | (m) |
| 2018-09-30 | $-18.50M | (m) | (m) | $6.20M | (m) | (m) |
| 2018-06-30 | $-15.27M | (m) | (m) | $5.10M | (m) | (m) |
| 2018-03-31 | $-14.67M | (m) | (m) | $4.70M | (m) | (m) |
| 2017-12-31 | $-13.03M | (m) | (m) | $3.90M | (m) | (m) |
| 2017-09-30 | $-11.06M | (m) | (m) | $3.30M | (m) | (m) |
| 2017-06-30 | $-10.11M | (m) | (m) | $3.00M | (m) | (m) |
| 2017-03-31 | $-10.51M | (m) | (m) | $2.90M | (m) | (m) |
| 2016-12-31 | $-10.88M | (m) | (m) | $3.10M | (m) | (m) |
| 2016-09-30 | $-12.18M | (m) | (m) | $3.50M | (m) | (m) |
| 2016-06-30 | $-10.93M | (m) | (m) | $3.20M | (m) | (m) |
| 2016-03-31 | $-10.00M | (m) | (m) | $3.10M | (m) | (m) |
| 2015-12-31 | $-8.82M | (m) | (m) | $2.70M | (m) | (m) |
| 2015-09-30 | $-8.47M | (m) | (m) | $2.60M | (m) | (m) |
| 2015-06-30 | $-9.22M | (m) | (m) | $2.80M | (m) | (m) |
| 2015-03-31 | $-9.07M | (m) | (m) | $2.90M | (m) | (m) |
| 2014-12-31 | $-9.22M | (m) | (m) | $2.90M | (m) | (m) |
| 2014-09-30 | $-3.41M | (m) | (m) | $2.90M | (m) | (m) |
| 2014-06-30 | $-3.31M | (m) | (m) | $2.80M | (m) | (m) |
| 2014-03-31 | $-3.97M | (m) | (m) | $2.80M | (m) | (m) |
| 2013-12-31 | $-4.02M | $6.00M | (m) | $2.70M | (m) | -66.97% |
| 2013-09-30 | $-9.87M | $37.25K | (m) | $3.21M | (m) | -26491.88% |
| 2013-06-30 | $-9.99M | $121.04K | (m) | $3.29M | (m) | -8252.96% |
| 2013-03-31 | $-9.49M | $614.66K | (m) | $3.83M | (m) | -1543.84% |
| 2012-12-31 | $-10.95M | $802.58K | (m) | $5.01M | (m) | -1363.77% |
| 2012-09-30 | $-12.03M | (m) | (m) | $5.68M | (m) | (m) |
| 2012-06-30 | $-13.57M | (m) | (m) | $6.48M | (m) | (m) |
| 2012-03-31 | $-15.01M | (m) | (m) | $7.04M | (m) | (m) |
| 2011-12-31 | $-16.11M | (m) | (m) | $7.78M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-17.88M | (m) | (m) | $9.71M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-21.24M | (m) | (m) | $10.87M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |